Marché des réactifs et équipements de transfection au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et perspectives du marché des réactifs et équipements de transfection au Moyen-Orient et en Afrique

La transfection implique l'introduction d'acide nucléique dans les cellules eucaryotes par des méthodes virales et non virales. La méthode de transfection peut surmonter le défi du transfert de la membrane chargée négativement. Des produits chimiques tels que le phosphate de calcium et le diéthylaminoéthyl (DEAE)-dextran ou un réactif à base de lipides cationiques réagissent avec la couche externe de l'ADN. Il neutralise la charge négative globale, confère la quantité positive à la molécule et permet ainsi la délivrance de l'ADN. Des méthodes physiques telles que l'électroporation créent des pores minuscules dans la membrane cellulaire en appliquant une tension électrique, permettant l'entrée de l'ADN directement dans le cytoplasme. Le DEAE-dextran est utilisé pour la transfection transitoire ; cependant, la lipofection peut réaliser une transfection stable et peut donc être utilisée pour l'expression protéique à long terme. La transfection médiée par le phosphate de calcium peut également être utilisée pour une transfection stable. La méthode de transfection virale atteint une efficacité élevée et est utilisée pour plusieurs phases du développement de produits pharmaceutiques.

La méthode de transfection est utilisée dans plusieurs applications agricoles pour la protection des cultures et l'amélioration du rendement, pour la production de produits de biologie synthétique pour améliorer les saveurs et les parfums, et pour améliorer les protéines unicellulaires, entre autres. La demande de transfection a augmenté dans les pays développés et en développement, et la raison en est l'apparition croissante de maladies chroniques. Le marché de la transfection est en croissance en raison de la demande croissante de gènes chimériques et de l'utilisation de produits biopharmaceutiques dans la production de protéines. Le marché va croître au cours de la période de prévision en raison de l'exploration des marchés émergents, des initiatives stratégiques des acteurs du marché et du soutien croissant des gouvernements.

Le coût élevé des instruments, l’efficacité sélective des réactifs de transfection et les dommages cellulaires induits par les méthodes de transfection devraient freiner la croissance du marché des réactifs et équipements de transfection au Moyen-Orient et en Afrique.

The market is growing due to several strategic initiatives adopted by market players involving acquisition, collaboration, and partnership.

Data Bridge Market Research analyzes that the Middle East and Africa transfection reagent and equipment market is expected to reach the value of USD 36,134.85 thousand by 2030, at a CAGR of 7.0% during the forecast period.

Market Definition

The transfection method is used to introduce RNA, DNA or protein products in cells to alter the phenotype and genotype of the organism. The transfection method involves the new gene transfer or transferring a gene construct such as Clustered regularly interspaced short palindromic repeats (CRISPR) for genome editing purposes. Transfection has wide applications in the field of immunotherapy, gene therapy, and cell therapy, among others. Transfection involves both non-viral and viral-mediated transfection. The chemical and physical methods can achieve non–viral transfection. The most common chemical method used for transfection is calcium phosphate transfection, and liposome transfection, among others. Viral transfection yields high transfection efficiencies, and various types of physical methods employed for transfection include microinjection, biolistic particle delivery, and electroporation, among which electroporation provides high transfection efficiency. Transfection is of two types either it can be transient or stable transfection. For short-term gene expression studies such as gene knock-out studies, small-scale production transient transfection method is preferred; however, long-term research studies and large-scale protein production stable transfection methods are widely adopted.

Middle East and Africa Transfection Reagent and Equipment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• RISE IN THE PREVALENCE OF CHRONIC DISEASES

The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. The transfection method is also used for the delivery of the CRISPR gene, which can enhance adaptive immunity and prevent an individual from different diseases.

The increasing cases of chronic diseases such as COVID-19 and other infectious diseases have led to the discovery of effective gene therapy products which can replace the defective gene with the correct gene. The transfection method is widely used for gene therapy, among others. As the demand for effective and accurate treatment is increasing worldwide, the demand for gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy to have the potential for chronic disease treatment are also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is acting as a driver for the Middle East and Africa transfection Reagent and equipment market growth.

• DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

Synthetic biology is a new era of biology that incorporates the engineering principle into biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand for synthetic biology products is increasing worldwide, the use of transfection products is also increasing.

The demand for synthetic biology products is increasing due to the increasing demand for effective and innovative products. The manufacturing of synthetic products enhances the demand for transfection products, as gene transfer can be accompanied by the transfection method, among others. Thus, this signifies that synthetic product development drives the Middle East and Africa transfection Reagent and equipment market growth.

Restraint

• CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

Some transfection methods have been reported to cause cell damage, reducing the reproducibility of the overall method. Among the several kinds of transfection procedures, electroporation has been reported to cause maximum cell damage as per the increase in voltage. This cell damage lowers the efficiency rate and impacts the ongoing project.

One of the most common side effects of the transfection procedure is cell damage which lowers the cells metabolic events and leads to cell death. This damaged cell can enhance the media toxicity and hence produces inappropriate results. Thus, this suggests that cell damage induced by the transfection procedure acts as a restraint for the Middle East and Africa transfection Reagent and equipment market growth.

Opportunity

• EXPLORATION OF EMERGING MARKET

The transfection products have been shown as promising tools for the genetic engineering and proteomic industry. The top market for transfection products is in Europe and North America. By looking at the positive outcomes of these products, many market players are penetrating their roots in growing economies involving China and India, among others. The emerging market allows these market players to combat the loss that arises from the well-established market.

As emerging markets allow the market players to overcome the economic downturn specified to particular established markets, investment and exploration of emerging markets allow the market players to engage in the development and manufacturing of transfection products to attain lucrative growth. Thus, this signifies that exploring emerging markets is an opportunity to grow the Middle East and Africa transfection Reagent and equipment market.

Challenge

• LONG APPROVAL PROCEDURE

The long approval procedure for transfection Reagent and instruments is a hindering agent for the growth of the transfection market. Transfection products are subjected to extensive regulations and have to monitor every time. The transfection products are widely used for the insertion of desired gene molecules in a particular cell line to obtain proteins and other biological compounds. This process is thus investigated and approved by the long and strict regulatory procedures. The long process required to get a positive result from every conducted clinical trial led to more time consumption and the investment of lots of money by market players.

The transfection Reagent are mostly subjected to 21CFR parts 210 and 211 U.S. FDA guidelines, according to which the manufacturers had to assure that the reagent manufactured meets the safety, packaging and processing characteristics proposed by the regulatory agencies. The owner or manufacturer has to submit licenses under section 351 of the PHS (Public Health Services) Act, which is quite a tedious procedure. Thus, this signifies that long approval procedures challenge the Middle East and Africa transfection Reagent and equipment market growth.

Recent Developments

• In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent, is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
• In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.

Middle East and Africa Transfection Reagent and Equipment Market Scope

Middle East and Africa transfection Reagent and equipment market is segmented into nine notable segments such as products, stage, methods, type, types of molecule, application, end user, organism, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

PRODUCTS

• INSTRUMENTS
• REAGENT & KITS

On the basis of products, the Middle East and Africa transfection reagent and equipment market is segmented into instruments and reagent & kits.

STAGE

• RESEARCH
• PRECLINICAL
• CLINICAL PHASES
• COMMERCIAL

On the basis of stage, the Middle East and Africa transfection reagent and equipment market is segmented into research, preclinical, clinical phases and commercial.

TYPE

• TRANSIENT TRANSFECTION REAGENT AND EQUIPMENT
• STABLE TRANSFECTION REAGENT AND EQUIPMENT

On the basis of type, the Middle East and Africa transfection reagent and equipment market is segmented into transient transfection reagent and equipment and stable transfection reagent and equipment.

METHODS

• NON-VIRAL METHODS
• VIRAL METHODS

On the basis of methods, the Middle East and Africa transfection reagent and equipment market is segmented into non-viral methods and viral methods.

TYPES OF MOLECULE

• PLASMID DNA
• DNA OLIGONUCLEOTIDES
• SMALL INTERFERING RNA (SIRNA)
• PROTEINS
• RIBONUCLEOPROTEIN COMPLEXES (RNPS)
• OTHERS

On the basis of types of molecule, the Middle East and Africa transfection reagent and equipment market is segmented into plasmid DNA, DNA oligonucleotides, small interfering RNA (siRNA), proteins, ribonucleoprotein complexes (RNPs) and others.

ORGANISM

• BACTERIA
• MAMMALIAN CELLS
• FUNGI
• PLANTS
• VIRUS

On the basis of organism, the Middle East and Africa transfection reagent and equipment market is segmented into bacteria, mammalian cells, fungi, plants and virus.

APPLICATION

• BY TYPE
  • IN VITRO APPLICATION
  • IN VIVO APPLICATION
  • BIOPRODUCTION
  • OTHERS
• BY INDUSTRY
  • AGRICULTURE
  • SYNTHETIC BIOLOGY
  • OTHERS

On the basis of application, the Middle East and Africa transfection reagent and equipment market is segmented by type into in vitro application, in vivo application, bioproduction, others and by industry into agriculture, synthetic biology, others.

END USER

• BIOPHARMA
• CROS
• CMOS/CDMOS
• ACADEMIA
• HOSPITALS
• CLINICAL LABS
• OTHERS

On the basis of end user, the Middle East and Africa transfection reagent and equipment market is segmented into biopharma, CROs, CMOs/ CDMOs, academia, hospitals, clinical labs and others.

DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES
• OTHERS

On the basis of distribution channel, the Middle East and Africa transfection Reagent and equipment market is segmented into direct tender, retail sales and others.

Middle East and Africa Transfection Reagent and Equipment Market Regional Analysis/Insights

The Middle East and Africa transfection reagent and equipment market is categorized into many notable segments such as geography, products, stages, methods, type, types of molecule, application, end user, organism, and distribution channel.

The countries covered in this market report are South Africa, Saudi Arabia, UAE, Israel, Egypt, and Rest of the Middle East and Africa.

South Africa dominates Middle East and Africa region due to due to increasing rare and chronic diseases.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des réactifs et équipements de transfection au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché des réactifs et équipements de transfection au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché des réactifs et équipements de transfection au Moyen-Orient et en Afrique.

Certains des principaux acteurs opérant sur ce marché sont Mirus Bio LLC., Promega Corporation, Polyplus Transfection, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Altogen Biosystems, SBS Genetech, FUJIFILM Irvine Scientific (une filiale de FUJIFILM Holdings Corporation), Avanti Polar Lipids (une filiale de Croda International Plc), PerkinElmer chemagen Technologie GmbH (une filiale de PerkinElmer Inc.), Cytiva, Geno Technology Inc., USA, R&D Systems, Inc., Takara Bio Inc., Thermofisher Scientific Inc., Roche Molecular Systems, Inc. (une filiale de F. Hoffmann-La Roche Ltd), QIAGEN, OriGene Technologies, Inc., Applied Biological Materials Inc. (abm), Beckman Coulter, Inc. (une filiale de Danaher), Amyris, Codexis, Autolus, SignaGen Laboratories, Impossible Foods Inc., Genlantis Inc., Ginkgo Bioworks, Verve Therapeutics, Inc., Conagen, Inc., Poseida Therapeutics, Inc. et Twist Bioscience, entre autres.

SKU-69834